Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernesto Vigna

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
European Journal of Haematology|April 15, 2026
First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy RegimensSantino Caserta, Enrica Antonia Martino, Danilo Lofaro, et al.
British Journal of Haematology|March 29, 2026
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integrationSantino Caserta, Enrica Antonia Martino, Mamdouh Skafi, et al.
European Journal of Haematology|April 20, 2026
From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL ManagementEnrica Antonia Martino, Santino Caserta, Ernesto Vigna, et al.
Annals of Hematology|May 4, 2026
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohortFrancesco Mendicino, Giulio Caridà, Antonella Bruzzese, et al.
European Journal of Haematology|July 9, 2026
Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized CareEnrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
Leukemia & Lymphoma|August 23, 2008
The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methodsEugenio Lucia, Bruno Martino, Corrado Mammi, et al.
European Journal of Haematology|February 19, 2025
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging PerspectivesGiulio Caridà, Enrica Antonia Martino, Antonella Bruzzese, et al.
Drug Design, Development and Therapy|July 15, 2021
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of MyelomaFortunato Morabito, Giovanni Tripepi, Enrica Antonia Martino, et al.
European Journal of Haematology|April 27, 2026
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic MalignanciesSantino Caserta, Enrica Antonia Martino, Ernesto Vigna, et al.
British Journal of Haematology|July 22, 2014
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 casesMassimo Gentile, Francesca R Mauro, Davide Rossi, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
European Journal of Haematology|April 15, 2026
First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy RegimensSantino Caserta, Enrica Antonia Martino, Danilo Lofaro, et al.
British Journal of Haematology|March 29, 2026
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integrationSantino Caserta, Enrica Antonia Martino, Mamdouh Skafi, et al.
European Journal of Haematology|April 20, 2026
From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL ManagementEnrica Antonia Martino, Santino Caserta, Ernesto Vigna, et al.
Annals of Hematology|May 4, 2026
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohortFrancesco Mendicino, Giulio Caridà, Antonella Bruzzese, et al.
European Journal of Haematology|July 9, 2026
Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized CareEnrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
Leukemia & Lymphoma|August 23, 2008
The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methodsEugenio Lucia, Bruno Martino, Corrado Mammi, et al.
European Journal of Haematology|February 19, 2025
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging PerspectivesGiulio Caridà, Enrica Antonia Martino, Antonella Bruzzese, et al.
Drug Design, Development and Therapy|July 15, 2021
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of MyelomaFortunato Morabito, Giovanni Tripepi, Enrica Antonia Martino, et al.
European Journal of Haematology|April 27, 2026
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic MalignanciesSantino Caserta, Enrica Antonia Martino, Ernesto Vigna, et al.
British Journal of Haematology|July 22, 2014
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 casesMassimo Gentile, Francesca R Mauro, Davide Rossi, et al.
Pageof 12